Skip to main content
Insights into Imaging
Fig. 4 | Insights into Imaging

Fig. 4

From: Clinical value of 3'-deoxy-3'-[18F]fluorothymidine-positron emission tomography for diagnosis, staging and assessing therapy response in lung cancer

Fig. 4

Evaluating response to erlotinib therapy with [18F]FDG-PET and [18F]FLT-PET. [18F]FDG-PET (a) and [18F]FLT-PET (c) before start of treatment, and [18F]FDG-PET (b) and [18F]FLT-PET (d) after 1 week of treatment with erlotinib. [18F]FDG uptake is higher than [18F]FLT in the baseline scans. Erlotinib treatment decreases uptake of both radiotracers. The [18F]FLT scan after therapy shows minimal uptake indicating that erlotinib is effectively inhibiting proliferation. Reprinted with permission from JNM. This research was originally published in JNM. Kahraman et al. [43]

Back to article page